Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Research & Development (2016 - 2025)

Iovance Biotherapeutics has reported Research & Development over the past 12 years, most recently at $71.2 million for Q4 2025.

  • Quarterly results put Research & Development at $71.2 million for Q4 2025, up 14140.6% from a year ago — trailing twelve months through Dec 2025 was $302.6 million (up 44.52% YoY), and the annual figure for FY2025 was $300.3 million, up 8.7%.
  • Research & Development for Q4 2025 was $71.2 million at Iovance Biotherapeutics, down from $75.2 million in the prior quarter.
  • Over the last five years, Research & Development for IOVA hit a ceiling of $87.5 million in Q3 2023 and a floor of $500000.0 in Q4 2024.
  • Median Research & Development over the past 3 years was $76.7 million (2023), compared with a mean of $70.4 million.
  • Biggest five-year swings in Research & Development: plummeted 99.35% in 2024 and later surged 14140.6% in 2025.
  • Iovance Biotherapeutics' Research & Development stood at $76.6 million in 2023, then plummeted by 99.35% to $500000.0 in 2024, then surged by 14140.6% to $71.2 million in 2025.
  • The last three reported values for Research & Development were $71.2 million (Q4 2025), $75.2 million (Q3 2025), and $79.4 million (Q2 2025) per Business Quant data.